M.B.A, B.Sc, Chief Executive Officer, Augurex Life Sciences Corp.
Norma Biln is a leading figure in the Canadian Biotechnology sector recently recognized as one of Canada’s Most Powerful Women: Top 100 Award Winner in 2017. Throughout her 24 years in the life sciences she has worked along, built and led teams that have consistently exceeded corporate goals. Norma began her career in clinical research with Pfizer Pharmaceuticals after completing her Bachelor of Science in Physiology at McGill University. She continued her career in several capacities in sales management, marketing and market access with Pfizer Pharmaceuticals, Amgen and Abbott Laboratories. Before her role of CEO at Augurex, Norma worked in various senior management roles in Business Development, Commercial and Communications. She holds a Master of Business Administration, is the former Chair of the Board of Directors of BioTalent Canada, a member of the Board of Directors of Resverlogix Corp (TSX:RVX) and has recently joined the Board of Directors of New Ventures BC, the province’s premiere tech competition and early stage accelerator.
Presentation Title and Company Description
Clinical Dx Showcase: Digital Health: Merging Point-of-Care Testing & Data
Augurex is a privately held biotechnology company focused on the development and commercialization of autoimmune disease biomarkers that transform patient clinical management for better disease outcomes. The company brings innovative blood tests and digital solutions to market to better inform clinical assessments for more precise care. To learn more, visit www.augurex.com.